KDM1A microenvironment, its oncogenic potential, and therapeutic significance.
- Citation data:
Epigenetics & chromatin, ISSN: 1756-8935, Vol: 11, Issue: 1, Page: 33
- Publication Year:
- Captures 4
- Readers 4
- Mendeley 4
- Repository URL:
- Biochemistry, Genetics and Molecular Biology; Histone demethylation; Carcinogenesis; Acute myeloid leukemia; KDM1A; TLL
The lysine-specific histone demethylase 1A (KDM1A) was the first demethylase to challenge the concept of the irreversible nature of methylation marks. KDM1A, containing a flavin adenine dinucleotide (FAD)-dependent amine oxidase domain, demethylates histone 3 lysine 4 and histone 3 lysine 9 (H3K4me1/2 and H3K9me1/2). It has emerged as an epigenetic developmental regulator and was shown to be involved in carcinogenesis. The functional diversity of KDM1A originates from its complex structure and interactions with transcription factors, promoters, enhancers, oncoproteins, and tumor-associated genes (tumor suppressors and activators). In this review, we discuss the microenvironment of KDM1A in cancer progression that enables this protein to activate or repress target gene expression, thus making it an important epigenetic modifier that regulates the growth and differentiation potential of cells. A detailed analysis of the mechanisms underlying the interactions between KDM1A and the associated complexes will help to improve our understanding of epigenetic regulation, which may enable the discovery of more effective anticancer drugs.